AVBP (ArriVent BioPharma) Land And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Land And Improvements?

ArriVent BioPharma's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.

ArriVent BioPharma Land And Improvements Historical Data

The historical data trend for ArriVent BioPharma's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Land And Improvements Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Land And Improvements

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial							-	-	-	-	-

ArriVent BioPharma Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.